Trials / Completed
CompletedNCT05496075
Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia
Observational Study on Clinical Efficacy and Safety of Orlistat in Reducing Uric Acid in Overweight/Obese Patients With Hyperuricemia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Shanghai 10th People's Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To clarify the uric acid-lowering efficacy of orlistat in overweight/obese patients with hyperuricemia, and to evaluate the safety of orlistat treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orlistat | Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks. |
| DRUG | Orlistat placebo | Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks. |
Timeline
- Start date
- 2022-08-26
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2022-08-11
- Last updated
- 2023-12-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05496075. Inclusion in this directory is not an endorsement.